MOUNTAIN VIEW, Calif. (TheStreet) -- Check out the acceleration in the number of prescriptions written for Vivus' (VVUS) weight-loss pill Qsymia. The uptick starts at the beginning of July when Vivus was finally able to sell Qsymia in retail pharmacies instead of by mail order only.
Vivus has also started direct-to-consumer advertising of Qsymia.
Two weeks of surging script numbers isn't enough to draw any firm conclusions about a Qsymia marketing rebound but it's definitely something to watch closely.Meantime, the nascent launch of Arena Pharmaceuticals' (ARNA) Belviq looks underwhelming. At best, Belviq scripts are tracking in line with Qsymia's early performance (not depicted on the chart above.) But factor in the considerable number of free Belviq samples being given out -- as much as 60% of the total scripts to date -- and Arena's weight-loss pill has a long way to go to meet even diminished expectations. Vivus has not set a date to report second-quarter earnings report but the consensus sales estimate for Qsymia is just under $8 million. Here's a chart of the relative stock performance of Vivus and Arena since July 1: VVUS data by YCharts
But look what happens when Orexigen Therapeutics (OREX) is added to the chart: VVUS data by YCharts
Investors are definitely running up the value of Orexigen in anticipating of a positive outcome from the cardiovascular safety study of its weight-loss pill Contrave. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV